dynamics of repaglinide: potentially hazardous interaction between gemfibrozil and
repaglinide. Diabetologia 2003b;46:347–351.
Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P,
Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-
dependent inhibitor of CYP2C8: implications for drug–drug interactions. Drug
Metab Dispos 2006;34:191–197.
Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, Neuvonen PJ.
A potentially hazardous interaction between erythromycin and midazolam. Clin
Pharmacol Ther 1993;53:298–305.
Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S. An interaction between the
cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam
(CYP3A). Br J Clin Pharmacol 2001;52:555–561.
Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated
with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 1999;83:1146.
Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned
pharmaceutical companies (1964–1985). Br J Clin Pharmacol 1988;25:387–396.
Prueksaritanont T, Lin JH, Baillie TA. Complicating factors in safety testing of drug
metabolites: kinetic differences between generated and preformed metabolites.
Toxicol Appl Pharmacol 2006;217:143–152.
Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the
organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated
hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the
mechanism of the clinically relevant drug-drug interaction between cerivastatin and
gemfibrozil. J Pharmacol Exp Ther 2004;311:228–236.
Smith D, Schmid E, Jones B. Do drug metabolism and pharmacokinetic departments
make any contribution to drug discovery?Clin Pharmacokinet 2002;41:1005–1019.
Smith DA, Obach RS. Metabolites and safety: what are the concerns, and how should
we address them? Chem Res Toxicol 2006;19:1570–1579.
Smith DA, Obach RS. Seeing through the mist: abundance versus percentage.
Commentary on metabolites in safety testing. Drug Metab Dispos 2005;33:1409–
1417.
Soepenberg O, Dumez H, Verweij J, deJong FA, deJonge MJ, Thomas J, Eskens FA,
van Schaik RH, Selleslach J, Ter Steeg J, Lefebvre P, Assadourian S, Sanderink GJ,
Sparreboom A, van Oosterom AT. Phase I pharmacokinetic, food effect, and
pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in
patients with solid tumors. Clin Cancer Res 2005;11:1504–1511.
Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R,
Kearns GL, Bertino JS. Jr. Combined phenotypic assessment of CYP1A2,
CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with
the ‘‘Cooperstown cocktail’’. Clin Pharmacol Ther 2000;68:375–383.
Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting
polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X
receptor activation. J Pharmacol Exp Ther 2003;304:223–228.
Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics,
and clinical relevance. Clin Pharmacol Ther 2005;77:341–352.
REFERENCES 235